Industrial Revolution: The New Medical Device Acquirers
The first article in a two-part series, The Boston Consulting Group (BCG) explores the financial rationale driving the steady trend of M&A activity in the medical technology sector-as well as the business implications that result. Here, the authors examine the phenomenon of external players-industrial companies, conglomerates and others-acquiring companies and entering the medtech sector. The series draws on the valuation techniques, used by BCG's ValueScience Center, which combine proprietary discounted cash flow and relative valuation multiple models.
You may also be interested in...
Natural selection by the markets will ensure the largest device companies will win out over industrial newcomers in buying smaller players, maximizing value creation and growing larger and stronger.
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.